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The management of acute promyelocytic leukemia (APL) has changed over the past few years1-2. The
discoveiy of specific molecular abnormality (PML/RAR-cz gene product) has raised considerable
interest in the management of the disorder with All trans- retinoic acid (ATRA)3-5. The compound is
now being increasingly used for the remission-induction in APL. However, the drug is not free of side
effects. We report a potentially fatal side effect of the drug in two patients.
Case 1
A 23 year old lady presented with pancytopenia and was diagnosed to have APL. The patient also had
right basal consolidation at presentation. She was started on ATRA, at a dose 45 mg/rn2 in two divided
doses. It was planned that ATRA would be administered for a total of 90 days. She also received
antibiotic therapy consisting of Cloxacillin, Amikacin and Ceftazidime. On the 5th day of therapy, the
patient became acutely dyspnoeic and restless. On examination, the respiratory rate was 32/mm., BP
140/80mm Hg, Pulse 160/min, temperature 37°C. Auscultation of the chest revealed decreased breath
sounds on the left side. The chest x-ray showed infiltrates throughout the right lung with complete
opacification of the left hemithorax. Arterial blood gasses showed severe arterial hypoxemia. Because
of the continuously decreasing 02 saturation, the patient was intubated and ventilated. A chest tube was
passed on the left side which drained 650 ml of hemorrhagic fluid. A subsequent CBC revealed a total
leucocyte count of 28,400/uL. Dexamethasone 10 mg b.i.d. parenterally, was initiated immediately.
Subsequently, Cytosine Arabinoside ma dose of 100 mg/m2 was administered for five days and
Daunorubicin inadose of45 mg/m2 for two days. Overthe next several days, clinical as well as the
radiological picture improved. About 3 weeks after the acute episode, the chest x-ray showed complete
resolution of bilateral infiltrates and pleural effusion. The chest tube was removed and the patient was
subsequently extubated. The patient returned to the ward, where a bone marrow aspirate showed her to
be in complete remission.
Case 2
A 37 year old lady presented with history of menorrhagia and easy bruisability and was found to be
pancytopenic. Her full blood count revealed a hemoglobin of 8.4 g/dl total leucocyte count 0.9x10 /L
and platelet count 18x10 /L. The liver and renal function tests were within nonnal limits. The bone
marrow aspirate acute promyelocytic leukemia according to the FAB criteria. The patient was started
on remission - induction treatment with ATRA 45 mg/m2 daily intwo divided doses. On the 6th thy of
treatment, the white cell count increased to 19,000/uL and remained at this level over the next couple of
days. The patient became febrile and developed a hematorna on the right upper arm, which was painful,
warm, tender and resulted in limitation of movements at the elbow joint. Antibiotics were started but
the fevercontinued. Blood cultures remained negative. On the 8th day of treatment with ATRA, she
developed another hematoma in her right calf followed by one in left calf. Peripheral blood smear
showed persistent leukocytosis with left shifted neutmpbils. The fever continued to spike despite the
use of antibiotics. On the 21st day of treatment with ATRA, the patient suddenly became dyspnoeic and
tachypnoeic. The respiratory rate was found to be 42/min. Auscultation of the chest revealed bilateral
crepitations and there was severe hypoxemia. Chest x-ray showed bilateral fluffy infiltrates.
Dexamethasone 10 mg was injected immediately and an endotracheal tube passed. She also developed
oligurea and systemic hypotension and eventually succumbed to persistent severe hypoxemia.
Discussion 
Acute promyelocytic leukemia (APL) comprises 10% of all cases of acute myeloid leukemia6. The
disease is characterized by increased bleeding tendency, primarily due to disseminated intravascular
coagulation (DIC), which may occur in upto 80% cases of APL7. Although chemotherapy is highly
effective in inducing remissions, it may also exacerbate the DIC by rapidly releasing cytoplasmic
granules from the malignant promyelocytes8. The incidence of fatal hemorrhage during the course of
initial treatment is more than 30 percent8. The identification of a non- random chrornosomal
abnormality resolves within the first 48 hours of the treatment. The treatment is generally well
tolerated, except for modest degree of thy skin, cheilosis, nasal stuffness and itching13. However, in
about a quarter of patients, the side effects may assume life threatening proportions. These side effects
have beenreported to occur between the second day and the third week of the treatment and consist of
fever, respiratory distress, radiographic pulmonary infiltrates and pleural and pericardial effusions.
Collectively, these have beentenned togetheras the retinoic acid syndrome9,10,14. The pathophysiology
of the syndrome, is unclear, but clinically it resembles the capillary leak syndrome observed in patients
treated with cytokines10,15. It is postulated that the syndrome may be a consequence of the fusion
transcript activity on the intracellular adhesion molecules10. As the leukemic cells differentiate, they
migrate to the pulmonary capillary bed, express the adhesion molecules, liberate vasoactive cytokines,
which result in capillary leak and consequent clinical abnormalities. Similar changes occur in the
capillary bed of kidney, liver, skin and lymph nodes10,16. Multi-organ failure ensues and if the
syndrome is not recognized early and treated promptly, it may be rapidly fatal. The syndrome is
difficult to manage once established; however, dexamethasone 10mg i/v every 12 hours has been
shown to halt the proçress of rapidly evolving cellularevents in a number of patients 14. The patients
may require drainage of pleural effusion and mechanical ventilation may be necessary till the
resolutionof symptoms as was the case in our first patient.
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